Clinical Trials on Estrogen Receptor Positive Breast Cancer in Australia

Total 436 results

Genentech, Inc.

Completed

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

Breast Cancer

Belgium, Israel, United States, Spain, Denmark, Germany, Hong Kong, Russian Federation, Australia, New Zealand, Korea, Republic of, Malaysia, Singapore, Italy, Czech Republic, France, Peru, Canada, United Kingdom, Chile, Thailand, Argentin... and more
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) (CRYSTAL)

Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

Sweden, Australia, Brazil, Bulgaria, France, Italy, Korea, Republic of, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Hungary, Poland, Romania, Austria, Belgium, Finland, Netherlands, Slovakia, Greece, Ta... and more
Queen Mary University of London

Completed

Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer (IBIS II)

Breast Cancer

Ireland, United Kingdom, Switzerland, Australia, Belgium, Chile, Denmark, Finland, Germany, Hungary, Italy, Malta, Portugal, Turkey
Hoffmann-La Roche

Completed

A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer

Breast Cancer

Spain, Russian Federation, Austria, Italy, Germany, Portugal
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
GlaxoSmithKline

Completed

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Neoplasms, Breast

United States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121)

Breast Cancer

Canada, Belgium, Korea, Republic of, United States, China, Taiwan, Mexico, Brazil, Argentina, Australia, Italy, Spain, Turkey, Thailand, United Kingdom, Poland
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Breast Cancer

Italy, Belgium, Canada, United Kingdom, Argentina, Australia, Austria, Brazil, Bulgaria, China, Croatia, Denmark, Dominican Republic, Ecuador, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, Indonesia, Irelan... and more
Novartis Pharmaceuticals

Completed

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer (FACE)

Breast Cancer

China, United States, Belgium, Germany, Italy, Austria, Japan, Australia, Canada, Sweden, Switzerland, United Kingdom, Spain, Denmark, France, Ireland, Israel, Netherlands, Korea, Republic of, Norway
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, France, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Turkey, Brazil, Japan, Taiwan, Thailand, Canada, Singapore, Mexico, Argentina, Germany, India, Philippines, Poland, South Africa
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Breast Cancer

United States, France, Czechia, Italy, Korea, Republic of, Australia, Belgium, Brazil, Canada, Germany, Guatemala, Hong Kong, Hungary, Panama, Peru, Poland, Spain, Taiwan, United Kingdom, Colombia, Bosnia and Herzegovina, Chile, El... and more
Royal Marsden NHS Foundation Trust
Institute of Cancer Research, United Kingdom; National Health Service, United...

Active, not recruiting

Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (CORE)

Breast Cancer | Carcinoma, Non-Small-Cell Lung | Prostate Cancer

United Kingdom, Australia
Karolinska University Hospital
German Breast Group; Austrian Breast & Colorectal Cancer Study Group; Swedish...

Unknown

Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients (PANTHER)

Breast Cancer

Sweden, Germany, Austria
Eli Lilly and Company

Active, not recruiting

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

Breast Cancer

Canada, Germany, Australia, Japan, United States, Taiwan, Belgium, New Zealand, Italy, Israel, Spain, France, Netherlands, Mexico, Turkey, United Kingdom, Korea, Republic of, Austria, Puerto Rico, Sweden, Russian Federation, Greece, Slovaki...
MacroGenics

Terminated

MGC018 With or Without MGA012 in Advanced Solid Tumors

Melanoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Metastatic Castrate Resistant Prostate Cancer | Advanced Solid Tumor, Adult

Spain, United States, Australia, Poland
Sanofi

Terminated

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (AMEERA-5)

Breast Cancer

United States, Russian Federation, Italy, Australia, Belgium, France, Japan, Ukraine, Netherlands, Argentina, Canada, Portugal, Spain, Austria, Brazil, Bulgaria, Chile, China, Czechia, Finland, Georgia, Germany, Hungary, Korea, Republic... and more
Novartis Pharmaceuticals

Completed

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)

Breast Cancer

United States, France, Spain, United Kingdom, Austria, Germany, Taiwan, Australia, Italy, Israel, Russian Federation, Korea, Republic of, Hong Kong, Thailand, Canada, Hungary, Japan, Lebanon, Belgium, Bulgaria, Greece, Argentina, Peru, Czech... and more
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2)

Advanced Breast Cancer

China, Japan, United States, Taiwan, Canada, Korea, Republic of, Spain, Bulgaria, Turkey, Finland, Italy, Czechia, India, Slovakia, South Africa, Germany, Australia, Brazil, Greece, Puerto Rico, Belgium, Argentina, Switzerland, Poland, ... and more
Eisai Inc.
Eisai Limited

Completed

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

Russian Federation, Italy, Belgium, Canada, South Africa, France, United States, Switzerland, Argentina, Australia, Austria, Brazil, Croatia, Czechia, Hungary, Poland, Spain
Hoffmann-La Roche

Completed

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Breast Cancer

Austria, Bulgaria, Italy, Portugal, Romania
AstraZeneca

Completed

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM)

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Australia
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (TH3RESA)

Breast Cancer

Belgium, Israel, Spain, Sweden, United States, Switzerland, Russian Federation, Czech Republic, France, Canada, Germany, Korea, Republic of, Australia, Hungary, Thailand, United Kingdom, Italy, Brazil, Slovakia, Poland, India, Norway
European Organisation for Research and Treatment...

Completed

Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

France, Thailand, Australia, Belgium, Netherlands, Slovenia, United Kingdom, Malaysia, Poland, Russian Federation, Philippines, Taiwan
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Breast Cancer

United States, Spain, Israel, Italy, Korea, Republic of, Belgium, Australia, Czechia, Japan, Brazil, France, United Kingdom, Turkey, Greece, Germany
AstraZeneca

Completed

Secondary Adjuvant Long Term Study With Arimidex (SALSA)

Breast Cancer

Austria
Alliance Foundation Trials, LLC.
Pfizer; Breast International Group; NSABP Foundation Inc; Austrian Breast & Colorectal... and other collaborators

Active, not recruiting

PALbociclib CoLlaborative Adjuvant Study (PALLAS)

Breast Cancer

United States, Spain, Italy, Ireland, United Kingdom, Australia, Germany, Japan, Portugal, Taiwan, Canada, Israel, Netherlands, Switzerland, Belgium, Austria, Hungary, Korea, Republic of, Mexico, Poland, Sweden
Celcuity, Inc.

Recruiting

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)

Breast Cancer

Korea, Republic of, United States, Belgium, United Kingdom, Taiwan, France, Italy, Australia, Singapore, Argentina, Canada, India, Mexico, Czechia, Spain, Austria, Bulgaria, Germany, Hungary, Poland, Brazil, Greece, Romania
Bristol-Myers Squibb

Completed

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

Breast Cancer

United States, India, Korea, Republic of, Taiwan, Spain, Germany, Austria, Italy, Peru, Russian Federation, Singapore, France, United Kingdom, Philippines, Argentina
Advanced Accelerator Applications

Terminated

[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR) (NeoFIND)

Breast Cancer | Small Cell Lung Cancer | Colorectal Cancer | Prostate Cancer | Non Small Cell Lung Cancer

Austria, France
Bristol-Myers Squibb

Completed

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)

Breast Cancer

China, Russian Federation, United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong, Ireland, Korea, Republic of, Mexico, Netherlands, Poland, Portuga... and more
AstraZeneca

Active, not recruiting

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291)

Locally Advanced (Inoperable) or Metastatic Breast Cancer

United States, Italy, Spain, Belgium, Hungary, Poland, Canada, France, Germany, Korea, Republic of, Japan, Peru, Russian Federation, United Kingdom, China, Taiwan, Israel, Australia, Argentina
Novartis Pharmaceuticals

Completed

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)

Breast Cancer

United States, China, Belgium, Canada, France, Italy, Taiwan, United Kingdom, Hungary, Australia, Spain, Germany, Singapore, Austria, Japan, Israel, Russian Federation, Korea, Republic of, Thailand, Slovakia, South Africa, Switzer... and more
Quadriga Biosciences, Inc.
Novotech (Australia) Pty Limited

Completed

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Melanoma | Sarcoma | Kidney Cancer | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Astrocytoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Thymic Carcinoma | Lung Cancer | Prostate Cancer | Brain Cancer | Cholangiocarcinoma | Bladder Cancer | Liver Cancer | Brain Metastases | Tongue Cancer | Esophagus... and other conditions

Australia
Novartis Pharmaceuticals
NCIC Clinical Trials Group

Completed

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Breast Cancer

United States, Belgium, Canada, United Kingdom, Argentina, Australia, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Taiwan, Thailand, India, Korea, Republic of, Mexico, Ukraine
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
Odonate Therapeutics, Inc.

Terminated

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)

Breast Cancer

Korea, Republic of, United States, Spain, Canada, Singapore, Taiwan, Australia, Belgium, Thailand, Hungary, Germany, United Kingdom, France, Ukraine, Austria, Czechia, Italy, Poland, Russian Federation
Medical University of Graz

Unknown

Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care

Quality of Life | Breast Cancer | Lung Cancer | Cholangiocarcinoma | Advanced Cancer | Pancreas Cancer | Colo-rectal Cancer | Symptoms and Signs

Austria
NSABP Foundation Inc
Hoffmann-La Roche; Genentech, Inc.; Cancer International Research Group (CIRG)

Terminated

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH)

Breast Cancer

Korea, Republic of, United States, Canada, Spain, Ireland, Australia, Argentina, China, United Kingdom, Germany, Brazil, Hong Kong, France, Israel, Taiwan, Serbia, Belgium, Thailand, Croatia, Egypt, Italy, Philippines, Bosnia and Herzegovina and more
The University of New South Wales
National Health and Medical Research Council, Australia; Novo Nordisk A/S; Sydney...

Completed

Rosiglitazone and Insulin in T1DM Adolescents

Type 1 Diabetes | Puberty: >Tanner 2 Breast Development or Testis >4ml

Australia
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Breast Cancer

United States, Canada, Spain, Belgium, China, Italy, Korea, Republic of, Taiwan, Australia, Japan, Brazil, France, Germany, United Kingdom, Hong Kong
Hoffmann-La Roche
Genentech, Inc.; Breast International Group

Active, not recruiting

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Breast Cancer

United States, Belgium, Canada, Australia, Austria, Bulgaria, China, Croatia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Panama, Slovenia, Spain, Taiwan, United Kingdom, Colombia, Czechia, El Salvador and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer

Breast Cancer

United States, Canada, Australia, Ireland
Puma Biotechnology, Inc.

Completed

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET)

Breast Cancer

United States, Spain, Korea, Republic of, China, United Kingdom, Canada, France, Australia, Denmark, Switzerland, Japan, Malaysia, Italy, Singapore, Taiwan, Belgium, Croatia, Czechia, Romania, Germany, Bahamas, Brazil, Bulgaria, Colombia and more
AstraZeneca

Completed

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

Breast Cancer | Metastasis

United States, Australia, Brazil, France, Italy, Mexico, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Poland, Japan, Argentina, Austria, Canada, Hungary, Israel, Netherlands, New Zealand, Portugal, Taiwan, Germany, Finlan... and more
University of Rostock
German Breast Group; German Cancer Aid

Active, not recruiting

Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery (INSEMA)

Breast Cancer

Austria, Germany
Stemline Therapeutics, Inc.

Active, not recruiting

Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD)

Breast Cancer

United States, Spain, Israel, Italy, Korea, Republic of, Australia, United Kingdom, Hungary, France, Portugal, Belgium, Ireland, Argentina, Austria, Canada, Denmark, Greece
Eli Lilly and Company
NSABP Foundation Inc

Active, not recruiting

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

Breast Cancer

United States, Spain, China, Germany, Taiwan, United Kingdom, Canada, Singapore, Italy, Australia, Japan, Hungary, Russian Federation, Belgium, New Zealand, Austria, India, Saudi Arabia, France, Czechia, Korea, Republic of, Finland, Argentin... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (AMALEE)

Breast Cancer

United States, South Africa, Austria, Hungary, Germany, Czechia, France, Russian Federation, Thailand, Belgium, Bulgaria, Lithuania, Jordan, Sweden, Finland, Peru, Colombia, Portugal, Canada, Brazil, India, Argentina, Costa Rica
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer

Pain | Breast Cancer | Prostate Cancer

United States, Australia, Peru, Puerto Rico
ETOP IBCSG Partners Foundation
NSABP Foundation Inc

Completed

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer (CALOR)

Breast Cancer

Spain, United States, Australia, Belgium, Switzerland, Canada, Peru, Netherlands, Hungary, South Africa

Clinical Trials on Estrogen Receptor Positive Breast Cancer in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations